Explain this page
Arphra AIPlain-English read on Global Partners LP’s valuation06-07today
- Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?10h
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend14h
- Is Global Partners (GLP) Stock Undervalued Right Now?1d
- NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets2d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$102.49
+140.69% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
11bull6bear
±5% threshold
Analyst PT consensus: $46.00 (+8.03%)
Candlestick · 1Y
Open in chart workstation →GLP
42.58-8.51%H 52.00L 40.83MA50 47.40MA200 —Avg vol 73K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.89% | -7.48% | -17.67% | -8.70% | -1.46% | +1.74% | -21.15% | +40.76% | +62.21% | +216.58% | +79.66% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$45.00
1 sh
Bid
$42.51
1 sh
Ask
$45.00
1,000 sh
Spread
$2.490
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $4.65B | $20.13M | $0.54 |
| Q3 Sep 2025 | $4.69B | $24.23M | $0.66 |
| Q2 Jun 2025 | $4.63B | $20.6M | $0.55 |
| Q1 Mar 2025 | $4.59B | $18.68M | $0.36 |
| Q4 Dec 2024 | $4.19B | $23.86M | $0.52 |
| Q3 Sep 2024 | $4.42B | $45.92M | $1.17 |
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?fool.com·Jun 20, 2026
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trendmarketbeat.com·Jun 20, 2026
- Is Global Partners (GLP) Stock Undervalued Right Now?zacks.com·Jun 19, 2026
- NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Marketsglobenewswire.com·Jun 18, 2026
- NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Marketsglobenewswire.com·Jun 18, 2026
- Ozempic Linked To Lower Risk Of Violence In New Studyforbes.com·Jun 17, 2026
- GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expandthenewswire.com·Jun 17, 2026
- GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expandaccessnewswire.com·Jun 17, 2026
Peers
No peer list available for GLP.
Total assets
$3.85B
Total debt
$1.62B
Cash & equiv
$12.24M
Operating CF
$284.8M
Free cash flow
$193.34M
Buybacks
-$10M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $18.56B | $191.28M | $79.22M | $2.11 | +0.43% |
| FY 2024 | $17.16B | $251.22M | $107.69M | $2.41 | +0.63% |
| FY 2023 | $16.49B | $243.77M | $152.51M | $3.76 | +0.92% |
| FY 2022 | $18.88B | $460.29M | $362.21M | $10.02 | +1.92% |
| FY 2021 | $13.25B | $142.22M | $60.8M | $1.77 | +0.46% |